Author

V. Baxter

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

E. Anderson· 4 shared M. T. Heise· 3 shared A. Schaefer· 2 shared E. A. Madden· 2 shared J. F. Loome· 2 shared K. L. Gully· 2 shared M. R. Zweigart· 2 shared R. S. Baric· 2 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

E. Anderson

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Lethal COVID-19 Associates With RAAS-Induced Inflammation For Multiple Organ Damage Including Mediastinal Lymph Nodes

J. W. Guarnieri, M. Topper, K. Beigel, J. A. Haltoom, A. Chadburn, J. Frere, J. An, H. Cope, A. Borczuk, S. Sinha, C. Lim, J. Kim, J. Park, C. Meydan, J. Foox, , K Clark

This study identifies non-canonical genes linked to RAAS overactivation in lethal COVID-19, causing multi-organ damage and mediastinal lymph node dysfunction.

bioRxiv · Oct 8, 2023 · PreprintImmunology

Pharmacokinetic considerations for optimizing inhaled spray-dried pyrazinoic acid formulations

S. B. Yeshwante, P. Hanafin, B. Miller, L. Rank, S. Murcia, C. Xander, A. Annis, V. Baxter, E. Anderson, B. Jermain, R. Konicki, A. Schmalstig, I. Stewart, M. Braunstein, A. Hickey, G. G. Rao

This study develops and evaluates inhaled POA formulations to improve TB treatment by enhancing pulmonary exposure and efficacy against pncA-mutant Mtb.

bioRxiv · Apr 1, 2023Pharmacology & Toxicology

Fc mediated pan-sarbecovirus protection after alphavirus vector vaccination

L. E. Adams, S. R. Leist, K. H. Dinnon, A. West, K. L. Gully, E. Anderson, J. F. Loome, E. Madden, J. Powers, A. Schaefer, S. Sarkar, I. Castillo, J. Maron, R. P. McNamara, H. L. Bertera, , R. S. Baric

This study shows that non-neutralizing antibodies targeting FcR4 and spike S2 provide cross-protection against sarbecoviruses after alphavirus vector vaccination.

bioRxiv · Nov 28, 2022Microbiology

A Multitrait Locus Regulates Sarbecovirus Pathogenesis

R. S. Baric, A. Schaefer, S. R. Leist, L. Gralinski, D. Martinez, E. S. Winkler, K. Okuda, P. E. Hawkins, K. L. Gully, R. L. Graham, T. D. Scobey, T. A. Bell, P. Hock, G. D. Shaw, J. F. Loome, , M. T. Ferris

The paper identifies a multitrait locus on mouse Chromosome 9 that regulates SARS-CoV, SARS-CoV-2, and bat sarbecovirus disease severity, with candidate genes CCR9 and CXCR6.

bioRxiv · Jun 1, 2022Microbiology